Related Contributions
Related Research Questions
Related Funding Opportunities
-
The Michael J. Fox Foundation for Parkinson's Research
-
The Michael J. Fox Foundation for Parkinson's Research
Related Clinical Trials
Related News
Related Events
-
03 Jun 2010 - 04 Jun 2010
-
14 Apr 2010 - 17 Apr 2010

Dr. Schwarzschild, I read your posting on PDOnlineResearch on Adagio, etc. with interest. I wonder if we are overlooking a fairly basic indicator of disease modification (nay, neuroprotection); the slope of the UPDRS vs. time lines. Eyeballing the Rasagiline lines, in comparison to the slope prior to administration of Rasagiline, shows in all cases a lower slope.
By contrast, the ELLDOPA lines within the acuity of my eyes, all have the same slope, suggesting no modification of progression.
Why would that not be a sufficient indication that Rasagiline lowers the rate of progression and ipso facto, modifies the disease progression?